Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  VIVUS, Inc.    VVUS

VIVUS, INC. (VVUS)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
07/13/2018 07/16/2018 07/17/2018 07/18/2018 07/19/2018 Date
0.771(c) 0.735(c) 0.75(c) 0.7548(c) 0.73(c) Last
317 328 456 515 300 569 142 884 373 829 Volume
-1.15% -4.67% +2.04% +0.64% -3.29% Change
More quotes
Financials (USD)
Sales 2018 60,0 M
EBIT 2018 -
Net income 2018 -
Debt 2018 -
Yield 2018 -
Sales 2019 60,0 M
EBIT 2019 -
Net income 2019 -
Debt 2019 -
Yield 2019 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales2018 1,33x
Capi. / Sales2019 1,33x
Capitalization 79,5 M
More Financials
Company
VIVUS, Inc. engages in the development and commercialization of novel therapeutic products.Its products include Qsymia and STENDRA/SPEDRA. The company was founded by Virgil A. Palace in April 16, 1991 and is headquartered in Mountain View, CA. 
Sector
Pharmaceuticals
Calendar
08/02Earnings Release
More about the company
Latest news on VIVUS, INC.
07/10VIVUS INC : Other Events, Financial Statements and Exhibits (form 8-K)
AQ
07/10VIVUS Announces Positive Results from a Phase 1 Clinical Trial of VI-0106
GL
06/19VIVUS INC : Change in Directors or Principal Officers (form 8-K)
AQ
06/12VIVUS : Executes on its Strategic Vision with the Closing of its Acquisition of ..
AQ
06/11VIVUS INC : Entry into a Material Definitive Agreement, Completion of Acquisitio..
AQ
06/11VIVUS Executes on its Strategic Vision with the Closing of its Acquisition of..
GL
05/30VIVUS, INC. : Complimentary Technical Snapshots on VIVUS and Three More Biotech ..
AC
05/18VIVUS INC : Other Events (form 8-K)
AQ
05/14VIVUS INC : Results of Operations and Financial Condition, Financial Statements ..
AQ
05/09VIVUS : 1Q Earnings Snapshot
AQ
More news
Sector news : Biopharmaceuticals
07/19AMGEN : and Cedars-Sinai in Collaboration for 'Health-Care Quality'
DJ
07/19MERCK AND : to Limit Drug-Price Increases, Cut Some Prices
DJ
07/19MERCK AND : Announces Plan to Lower Prices of Some Drugs
DJ
07/19JOHNSON & JOHNSON : Women who sued J&J declare victory after $4.69 billion talc ..
RE
07/19Barclays Poaches Senior Health-Care Banker From Deutsche Bank
DJ
More sector news : Biopharmaceuticals
4-Traders Strategies on VIVUS, INC. 
VIVUS - 2013
Bearish trend should continue
SELL
More Strategies
Latest Tweets
12:07aZacks: Brokerages Expect VIVUS, Inc. $VVUS Will Announce Earnings of -$0.11 P.. 
12:03aVIVUS, Inc. $VVUS Expected to Post Earnings of -$0.11 Per Share  
07/19VIVUS $VVUS Downgraded to “Hold” at Zacks Investment Research  
07/18$VVUS New Form PRE 14A for VIVUS Inc. From our Stock News Alerts App 
07/17$VVUS New Form 4 for VIVUS Inc. From our Stock News Alerts App 
More tweets
Qtime:75
News from SeekingAlpha
07/12YOUR DAILY PHARMA SCOOP : Kamada Phase 3 Approved, Vivus Positive, IsoRay Down 
07/10Vivus up 15% premarket on positive data for PAH candidate VI-0106 
05/27WEEK 22 BREAKOUT FORECAST : Short-Term Picks To Give You An Edge 
05/08Vivus' (VVUS) CEO John Amos on Q1 2018 Results - Earnings Call Transcript 
05/08Vivus beats by $0.01, misses on revenue 
Chart VIVUS, INC.
Duration : Period :
VIVUS, Inc. Technical Analysis Chart | VVUS | US9285511005 | 4-Traders
Technical analysis trends VIVUS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 1
Average target price 1,50 $
Spread / Average Target 99%
EPS Revisions
Managers
NameTitle
John P. Amos Chief Executive Officer & Director
Thomas Braxton King President & Independent Director
David York Norton Chairman
Scott Oehrlein Chief Operating Officer
Mark K. Oki Chief Financial & Accounting Officer
Sector and Competitors
1st jan.Capitalization (M$)
VIVUS, INC.50.18%80
BIOGEN12.54%74 904
CSL LIMITED41.27%66 152
ALEXION PHARMACEUTICALS13.43%30 349
BIOMARIN PHARMACEUTICAL15.16%18 364
GRIFOLS2.52%18 309